Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cellectis Announced Collaboration Agreement with Stemgent

Published: Monday, March 11, 2013
Last Updated: Sunday, March 10, 2013
Bookmark and Share
Agreement to provide custom genome-engineered iPS cells.

Cellectis Bioresearch has announced a collaboration agreement with Stemgent, Inc. to provide research services that combines mRNA reprogramming technology and genome engineering.

The partnership marries Cellectis bioresearch’s leadership in genome engineering with Stemgent’s expertise in cellular reprogramming.

Stemgent’s proprietary mRNA reprogramming technology addresses the challenges around deriving non-viral non-integrating clinically-relevant induced pluripotent stem (iPS) cells for use in regenerative medicine drug discovery and basic research.

Traditional reprogramming methods can lead to the integration of unwanted genetic material into the host genome and therefore can be disruptive to the reprogrammed cell’s function.

Targeted genome engineering is a powerful technology that can be used to elucidate the genetic basis of diseases and to evaluate drug candidates through the generation of cell-based assays.

Cellectis bioresearch’s TALEN™-based genome engineering technology enables the directed introduction of disease-specific genetic mutations to mimic disease and of reporter genes with fluorescent/luminescent tags to evaluate drug candidate efficacy specificity and toxicity.

Together these two powerful technologies pave the way for clinically-relevant applications in regenerative medicine.

Cellectis Group CEO André Choulika said “The collaboration between Stemgent and Cellectis fits with our mission to enable scientists worldwide with the tools to generate genome-engineered iPS cells for use in their research and regenerative medicine.”

“Drug toxicity testing is an important part of early-stage drug development continued Ian Ratcliffe Stemgent President and CEO. “The challenge researchers face is that current models to test drugs are often inadequate. With this partnership and the combined technologies we can introduce mutations into reprogrammed cells and differentiate them into downstream lineages. Researchers can utilize these cells to test how mutations known and unknown alter the biology of the cells upon exposure to drugs.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Manufactured Stem Cells to Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Starving Stem Cells May Enable Scientists To Build Better Blood Vessels
Researchers from the University of Illinois at Chicago College of Medicine have uncovered how changes in metabolism of human embryonic stem cells help coax them to mature into specific cell types — and may improve their function in engineered organs or tissues.
Long-Term Culturing of Adult Stem Cells
A new procedure developed by Harvard Stem Cell Institute researchers (HSCI) at Massachusetts General Hospital (MGH) may revolutionize the culturing of adult stem cells.
Naked Mole Rat Exhibits “Extraordinary” Cancer Resistance
Scientists are getting closer to understanding the anti-cancer mechanism of the naked mole rat by making induced pluripotent stem cells.
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
Reclaiming The Immune System's Assault On Tumors
EPFL study shows a way to reclaim corrupted immune cells.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Body’s Own Gene Editing System Generates Leukemia Stem Cells
Inhibiting the editing enzyme may provide a new therapeutic approach for blood cancers.
Cirrhosis-Causing Cells Converted to Healthy Liver Cells in Mice
New approach that repairs liver from within may be more efficient than cell transplants.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!